The ICR will
need to be updated if changes are made between phases or between
pretests and the main studies.
Inventory as of this Action
Requested
Previously Approved
08/31/2023
36 Months From Approved
8,163
0
0
1,823
0
0
0
0
0
This ICR collects information from
healthcare professionals (physicians, PAs, NPs and pharmacists)
through two surveys of aimed at obtaining information about their
knowledge, attitudes, experiences about abuse-deterrent formulation
opioids (ADFs), including related to the ADF terminology. One of
the surveys will collect representative data in these areas; the
second survey, which will follow the first, will experimentally
test the ADF term (the control) against three alternative terms
derived, in part, from the general survey to objectively and
subjectively determine which term elicits the greatest accuracy in
understanding about these products and minimizes knowledge gaps and
misperceptions that surfaced in the first qualitative phase of this
research as well as in other research. The two surveys described in
this ICR make up the second and third phases of a three-phase
research project and were informed by the findings obtained from
focus groups with healthcare professionals in Phase 1.
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.